PLT 012
Alternative Names: EI-012; PLT-012Latest Information Update: 18 Dec 2025
At a glance
- Originator Elixiron Immunotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD36 antigen antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Yes - Liver cancer; Cholangiocarcinoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders; Liver cancer; Liver metastases; Solid tumours
Most Recent Events
- 15 Dec 2025 US FDA approves IND application for PLT 012 in Solid tumours
- 15 Dec 2025 Pilatus Biosciences plans a phase I first in human trial for Solid tumours in first quarter of 2026
- 30 Oct 2025 Pilatus Biosciences plans a phase I first-in-human trial for Liver cancer (Combination therapy) in the USA (Parenteral) in Q1 2026